Ph+ ALL Guideline Updates 2024 : Episode 2

Opinion

Video

January 2, 2025

Evolving Treatment Paradigms in Ph+ ALL

Dr. Bijal Shah explores the recent advancements and shifts in treatment strategies for Ph+ ALL, driven by innovations in targeted therapies and evolving clinical practices

EP: 1.Guidelines as a Framework for Improved Outcomes in Ph+ ALL

Now Viewing

EP: 2.Evolving Treatment Paradigms in Ph+ ALL

How has the treatment approach for Ph+ ALL evolved in recent years?

Related Content

January 3rd 2025

New Generation of CAR T May Elicit Improved CR Rates in CLL

AJMC Contributor

A third-generation chimeric antigen receptor (CAR) T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Mehrdad Mobasher, MD, MPH | Image credit: BeiGene

January 2nd 2025

BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024

Mary Caffrey

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

December 30th 2024